OncoMatch/Clinical Trials/NCT06756334

Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis

Is NCT06756334 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including [18F]AlF-PSMA-N5 and [18F]F-DCFPyL for prostate cancer.

Early Phase 1RecruitingAnhui Provincial HospitalNCT06756334Data as of May 2026

Treatment: [18F]AlF-PSMA-N5 · [18F]F-DCFPyL — To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \[18F\]AlF-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \[18F\]F-DCFPyL.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Biomarker criteria

Required: FOLH1 imaging avidity

simultaneous [18F]AlF-PSMA-N5 and [18F]F-DCFPyL examinations within two weeks

Required: FOLH1 imaging avidity

simultaneous [18F]AlF-PSMA-N5 and [18F]F-DCFPyL examinations within two weeks

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify